Shares of Navidea Biopharmaceuticals (NAVB -4.3%) trade lower out of the gate.
Behind the move looks to be Aegis, where, according to market chatter, analysts have cut their price target.
Reminder: Q3 Lymphoseek sales were $144K.
In other company news, NAVB says it will collaborate with the University of San Francisco "on a clinical study to evaluate, for the first time, the use and performance of technetiumlabeled tilmanocept in patients with Kaposi Sarcoma." (PR)